Biologics_Market.JPG

Biologics Market Size, Share & Trends Analysis Report By Source (Microbial, Mammalian, Others), By Product (MABs, Vaccines, Antisense, RNAi & Molecular Therapy, Recombinant Proteins, Others), By Disease (Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others), By Manufacturing (Outsourced, In-house), By Route of Administration, By Drug Classification, By Mode of Purchase, By Distribution Channel, By Region, And Segment Forecasts, 2025-2034

Report Id: 1729 Pages: 180 Published: 05 July 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global Biologics Market Size is valued at USD 426.1 Bn in 2024 and is predicted to reach USD 890.2 Bn by the year 2034 at a 7.8% CAGR during the forecast period for 2025-2034.

Biologics are drugs manufactured from organic materials that can treat various disorders, including immune-related illnesses such as Crohn's disease, psoriasis, ankylosing spondylitis, and rheumatoid arthritis. The intriguing feature is that biologics are isolated from various natural sources, whether carbohydrates, proteins, nucleic acids, or a complex mixture of these materials.

Biologics Market

The improved understanding of disease's genetic and molecular foundation has paved the way for creating various tailored treatments. Recmbinant proteins, for example, help the immune system identify and bind foreign molecules. Advances in manufacturing capability development are expected to increase biopharmaceutical production capacity. The use of single-use systems in the synthesis and processing of biopharmaceuticals is also among these breakthroughs.

However, the COVID-19 pandemic had a large market impact. During the pandemic, there was a huge demand for biologics, which contributed significantly to the market's rise. For example, the National Research Council of Canada and China-based CanSino Biologics collaborated on the development of a COVID-19 vaccine in Canada in May 2020. During the pandemic, the considerable research and development operations for the treatment of COVID-19 contributed considerably to the expansion of the biologics market. 

Recent Developments:

  • In February 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson obtained the United States Food and Drug Administration (FDA) approval for CARVYKTI (ciltacabtagene autoleucel; cilia-cel). This drug is used to treat adults with refractory or relapsed multiple myeloma (RRMM), including an a proteasome inhibitor, immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Competitive Landscape:

Some of the Biologics Market Players are:

  • Abbvie Inc.
  • Amgen
  • AstraZeneca
  • Bayer AG
  • Celltrion Inc.
  • Addgene
  • Eli Lilly & Company
  • Hoffmann-La Roche Ltd
  • GSK group of companies
  • Johnson & Johnson Services, Inc
  • Merck & Co. Inc
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Precision Biologics, Inc.
  • Samsung Biologics
  • Sanofi 

Market Segmentation:

The biologics market is segmented based on source, product, disease, manufacturing, route of administration, drug classification, mode of purchase, distribution channel. Based on source, the market is segmented as microbial, mammalian, and others. The products segment includes MABs, Vaccines, Antisense, RNAi & Molecular Therapy, Recombinant Proteins, Others. By disease category, the market is segmented into Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others. Manufacturing segment includes Outsourced, In-house, Route of Administration segment includes Oral and Others (IV and IP), Drug Classification segment includes Branded & Generic Drugs, Mode of Purchase segment includes Prescription & Over-The-Counter (OTC) Drugs, and Distribution Channel segment includes Hospital, Retail and online.

Based On The Source, The Microbial Segment Is A Major Contributor To The Biologics Market

The microbial category is expected to hold a major share of the global Biologics Market in 2022. This is attributed to the high number of medications developed by employing these products. Microbial expression systems commonly include E. Coli and yeast. Recombinant insulin, granulocyte-macrophage colony-stimulating factor, platelet-derived growth factor, and recombinant interferon are all products of these expression systems. Companies utilizing microbial systems include Johnson & Johnson, Novartis, and Genentech.

The Oncology Segment Witnessed Growth At A Rapid Rate

The oncology segment is projected to grow at a rapid rate in the global Biologics Market owing to the rising incidence of cancer coupled with the presence of different R&D programs. These efforts include cancer-eradication gene treatments and antisense therapeutics. Additionally, oncology is expected to retain its supremacy during the predicted period. The increased use of goods to lessen the number of adverse effects connected with the use of cancer chemotherapy is one of the drivers for the expected growth.

In The Region, The North America Biologics Market Holds A Significant Revenue Share

The North America Biologics Market is expected to register the highest market share in terms of revenue in the near future. This can be attributed to significant corporations, engaging reimbursement policies, and considerable R&D investment. In the United States, biologics account for around 38% of overall medication spending. Approval of new biologic drugs will likely boost market expansion throughout the projection period; for example, the US FDA approved 21 BLAs in 2021. Because of increased R&D spending for biologic development, as well as the availability of a high number of FDA-approved biologics in the country, the United States market for biologics will account for a considerable proportion in 2021. In addition, Germany holds the largest proportion of the European biologics market.

The presence of a sophisticated manufacturing sector, favorable reimbursement, the availability of several approved medications, and the target patient group all contribute to this market's supremacy in Europe.

Biologics Market Report Scope:

Report Attribute

Specifications

Market size value in 2024

USD 426.1 Bn

Revenue Forecast in 2034

USD 890.2 Bn

Growth rate CAGR

CAGR of 7.8% from 2025 to 2034

Quantitative units

Representation of revenue in US$ Bn and CAGR from 2025 to 2034

Historic Year

2021 to 2024

Forecast Year

2025-2034

Report coverage

The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends

Segments covered

Source, Product, Disease, Manufacturing, Route of Administration, Drug Classification, Mode of Purchase, Distribution Channel

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Competitive Landscape

Samsung BioLogics; Amgen; Novo Nordisk A/S; AbbVie Inc.; Sanofi; Pfizer Inc.; Inc.; GSK group of companies; Merck & Co., Celltrion; Precision Biologics, Inc.; Johnson & Johnson Services, Inc;  Eli Lilly and Company; Novartis AG; Merck KGaA; Bayer AG; F. Hoffmann-La Roche Ltd; and AstraZeneca

Customization scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and available payment methods

Explore pricing alternatives that are customized to your particular study requirements.


Deprecated: stripslashes(): Passing null to parameter #1 ($string) of type string is deprecated in /home/z8nbkwptb7pj/public_html/report-details.php on line 209

Segmentation of Biologics Market-

Biologics Market By Source

  • Microbial
  • Mammalian
  • Others

 biologics

Biologics Market By Product

  • MABs
  • Vaccines
  • Hormones
  • Therapeutic Enzymes
  • Recombinant Proteins
  • Antisense, RNAi & Molecular Therapy
  • Blood Factors and Anticoagulants
  • Allergenic extracts
  • Human Cells and Tissues
  • Proteins
  • Gene Therapies
  • Cellular Therapies
  • Others 

Biologics Market By Disease

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others 

Biologics Market By Manufacturing

  • Outsourced
  • In-house 

Biologics Market By Route of Administration

  • Oral
  • Others (IV and IP) 

Biologics Market By Drug Classification

  • Branded Drugs
  • Generic Drugs 

Biologics Market By Mode of Purchase

  • Prescription Drugs
  • Over The Counter (OTC) Drugs 

Biologics Market By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Biologics Market By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.
Frequently Asked Questions

Lateral Flow Assay Market Size is valued at USD 20.65 Bn in 2023 and is predicted to reach USD 24.45 Bn by the year 2031

Lateral Flow Assay Market is expected to grow at a 2.21% CAGR during the forecast period for 2024-2031.

Chembio Diagnostics, Inc., Orasure Technologies, DCN Diagnostics, Polysciences Inc., Abingdon Health, Oranoxis Inc., Aesku.Group Gmbh, Bio Group Medic

Releated Report Box